Bengaluru, May 25: Indian drug-maker Strides Shasun Ltd has got approval for its Memantine Hydrochloride tablets to treat Alzheimer’s-type dementia from the US regulator,said the company.
The 5mg and 10mg Memantine Hydrochloride tablets for treating moderate to severe Alzheimer’s-type dementia has been approved by US Food & Drug Administration (USFDA).
“The US market for Memantine Hydrochloride tablets is about $60 million. The product will be manufactured at our flagship facility in Bengaluru and marketed by Strides Pharma Inc in the US at the earliest,” said the filing.
Shasun has four business verticals, viz. Regulated Markets, Emerging Markets, Institutional Business and Active Pharmaceutical Ingredients.
The company has eight manufacturing footprint plants across three continents and three R&D facilities in India.